miRecule, Inc.
PrivateLast Round
Series A
Jul 14, 2024
Total Funding Raised
$38.56M
Company Overview
miRecule, Inc. is a biotechnology company developing RNA-based therapies for cancer and muscular dystrophy using its proprietary DREAmiR platform to create highly tailored therapeutics.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
miRecule, Inc. Comparables
Compare miRecule, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Avidity Biosciences | 80% | |
| Epicrispr Biotechnologies | 79% | |
| Novartis | 79% |
miRecule, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Jul 14, 2024 | ||||
| Strategic | Oct 4, 2022 | ||||
| Grant | Sep 29, 2022 | ||||
| Grant | Feb 28, 2022 | ||||
| Grant | May 27, 2021 | ||||
Seed | May 27, 2021 |
Key People
Founding team and executive leadership
miRecule, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| National Cancer Institute | Grant |
| Boutique Venture Partners | Seed |
| Solve FSHD | Grant |
| Alexandria Venture Investments | Seed |
| Pathway Bioventures | Seed |
| FSHD Society | Seed |
| University System of Maryland Momentum Fund | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 14, 2024
Completed a Series A funding round.
- Feb 28, 2022
Secured $100K in grant funding.
Recent news
Latest coverage and updates
- is_developingJul 31, 2026
Mirecule, Inc. was planning to develop novel peptide-RNA conjugates on Jul 31st '26.
- is_developingJul 31, 2026
Mirecule, Inc. is planning to develop RNA therapeutics for rare genetic diseases generation.
- partners_withJul 31, 2026
Mirecule, Inc. partnered with RBBL on Jul 31st '26.
- is_developingJul 31, 2026
Mirecule, Inc. is developing peptide-mediated delivery technologies on Jul 31st '26.
miRecule, Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about miRecule, Inc.'s valuation, stock price, and market status.
Is miRecule, Inc. a public or private company?
miRecule, Inc. is a private company.
What is the current stock price of miRecule, Inc.?
miRecule, Inc. is a private company with no public stock price. No recent secondary market data is available.
How much is miRecule, Inc. worth (valuation)?
Valuation information for miRecule, Inc. is not publicly available.
Can I buy miRecule, Inc. stock?
miRecule, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was miRecule, Inc.'s last funding round?
miRecule, Inc.'s most recent funding round was Series A on July 14, 2024.
Who are the main investors in miRecule, Inc.?
Key investors in miRecule, Inc. include Solve FSHD, Alexandria Venture Investments.
Will miRecule, Inc. IPO soon?
No public IPO plans have been announced for miRecule, Inc..
How can I track miRecule, Inc. secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor miRecule, Inc.'s secondary market activity and sign up for updates.